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If early intervention leads to better outcome 
can ‘earliest’ intervention prevent progress to 
frank psychosis or Delay it?
Clinical
Epidemiological 
Neuropsychological
Neurophysiological
Neuroimaging 
Animal Studies
Cognitive Neurosciences
Clinical studies of Early 
Psychosis initiative
‘At-Risk for Psychosis’
Challenges
• Significant public health merit
• Unfolding brain development & maturation in SZ.
• specificity in Non-specific symptoms
• Consensus in Definitions & Measurements
• Predictive validity of symptoms & Risk factors
• Biomarkers & behavioral markers of regional  brain 
dysfunction
• Argument for Intervention: when & how? 
Opening up windows of opportunities for 
identification & treatment
• ‘ How operationally benign the process 
was….”(McGlashan)
• Need to refine identification in adolescents
• Refining the criteria's prevention
• Medication trial = Medication free challenge
• Ongoing functional decline
• Suicide
• Homicide or risk
Genetics ,  familial,
Environmental Risk
Genetic High risk group (GHR)
Clinical High Risk Group ( CHR)
Ultra High Risk group ( UHR)
PET imaging showing areas of brain activity in twins - one schizophrenic, one not. 
Image courtesy Dr. Karen Berman, Clinical Brain Disorders Branch, NIMH, NIH)
Neuronal 
development & 
Child abuse
1.Chen TJ, Med Hypotheses. 2006;66(5):1043-4. 
2.Anda RF,Eur Arch Psychiatry Clin Neurosci. 2006 Apr;256(3):174-86. 2005
Childhood Experience and the 
Expression of Genetic Potential: 
What Childhood Neglect Tells Us 
About Nature and Nurture 1, 2
Commonly described prodromal features of 
schizophrenia (modified from Yung, 2006)
Neurotic symptoms
• Anxiety
• Restlessness
• Anger, irritability
Mood-related symptoms
• Depression
• Anhedonia
• Guilt
• Suicidal ideas
• Mood swings
Changes in volition
• Apathy, loss of drive
• Boredom, loss of interest
• Fatigue, reduced energy
Cognitive changes
• Disturbance of attention and
• concentration
• Preoccupation, daydreaming
• Thought blocking
• Reduced abstraction
Young AY& Mcgorry PD, Prediction of Psychosis: setting the stage,  BJP 2007, 191 suppl  51
Symptoms suggesting high risk 
The prodrome concept runs into problem Variability, lack of specificity 3
Physical symptoms
Somatic complaints
Loss of weight
Poor appetite
Sleep disturbance
Attenuated or sub-threshold versions of psychotic 
symptoms 1, 2
Perceptual abnormalities
Suspiciousness
Ideas of reference
Change in sense of self, others
or the world
Other symptoms
Obsessive–compulsive phenomena
Dissociative phenomena
Increased interpersonal sensitivity
Behavioral changes
Deterioration in role functioning
Social withdrawal
Impulsivity
Odd behavior
Aggressive, disruptive behavior
1.Tien, A.Y. (1991) Distributions of hallucinations in the population. Social Psychiatry and Psychiatric Epidemiology, 26, 287-292.
2.van Os, J.,Hanssen,M., Bijl, R.V., et al (2001) Prevalence of psychotic disorder and community level of psychotic symptoms: An urban-rural comparison. Archives of General Psychiatry, 58, 663-
668.
3.Young AY& Mcgorry PD, Prediction of Psychosis: setting the stage,  BJP 2007, 191 sp 51
Stage 0
Increased risk of psychotic disorder
• No symptoms currently
Stage 1a
Mild or non-specific symptoms, including 
neurocognitive deficits Mild functional change 
or decline
Stage 1b
Ultra-high risk: moderate but subthreshold 
symptoms, with moderate neurocognitive 
changes and functional decline. 
Stage 2
First episode of psychotic disorder Full 
threshold disorder with moderate^ severe 
symptoms, neurocognitive deficits and 
functional decline (Global Assessment of 
Functioning (GAF) 30-50)
UTILITY OF A CLINICAL STAGING MODEL1
(e.g. malignancy ) QOL & Survival depends upon  earliest possible intervention
 fundamental assumptions
 early stages  better response 
 treatments  offered likely  benign & effective.2
1.Young AY& McGorry PD, Prediction of Psychosis: setting the stage,  BJP 2007, 191 sp 51
2.McGorry, P.D.,Hickie, I. B.,Yung, A. R., et al (2006) Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective 
interventions. Australia and New Zealand Journal of Psychiatry, 40, 616^622. 
Stage 3a
Incomplete remission from
first episode of care
Stage 3b
Recurrence or relapse of psychotic 
disorder which stabilizes  with 
treatment at a level of GAF, residual 
symptoms, or neurocognition below 
the best level achieved following 
remission from first episode
Stage 3c
Multiple relapses, 
provided 
worsening in clinical extent and 
impact of illness is objectively 
present
Stage 4.
Severe,persistentor unremitting illness as 
judged on symptoms, neurocogntion and 
disability criteria 
Note: could fast track to this stage at first 
presentation through specific clinical and 
functional criteria (from stage 2) or alternatively 
by failure to respond to treatment 
(from stage 3a
Young AY& Mcgorry PD, Prediction of Psychosis: setting the stage,  BJP 2007, 191 sp 51
Detect sub threshold 
symptoms
Psychotic-like-experiences 
(PLE)
Level 2 
other Psychiatric 
syndromes with 
incidental PLE
Level 3, 
PLEs associated with Distress, 
help-seeking, reduced 
functioning, Comorbidity, 
Level 4
First episode psychosis, frank 
Symptoms
Level 5 
Schizophrenia
Level 0, No Psychiatric Symptoms
Level 1 PLEs No distress , 
Help seeking, poor 
functioning,
co morbidity
Substance use 
• Prospective studies : ‘.SU contribute to the onset’ 1
• ‘irrespective’ of identified risk 
• Cannabis use increases likelihood of psychotic relapse 2
• Increased psychotic experiences –in non-clinical general population 3
• Neither use nor dependence (  1 year prior ) -- associated with  higher risk 
in  F/U 1 Y
• High levels use  less motivated to seek Tx. 4
• Edinburgh study,: ‘more likely to have  psychotic-like symptoms at 
baseline’ 5
• No longitudinal data  for transition to psychosis
1.Hornicroft, 1990,  2.Linszen et al, 1994), 3.Johns et al, 2004 (PACE cohort ) 4.Phillips et al, 2002a, 5.Miller et al, 2001 
Cannabis : contrasting results, 
‘role of cannabis as a risk  for onset of psychosis’.
Stress
Adverse Life Events ( ALE)
• Precede onset 1
• Cause Relapses in established  
disorders 2
• Hypothesis: ALE may actually 
precipitate onset in vulnerable 
individuals.
• Minor life events or day-to-day 
hassles: are more stressful  than 
major events 3
• Subjective experiences of stress, 
• More intense negative 
affect to subjective 
appraisals 4
• Difference in tolerance
– psychotic like symptoms
– lifetime experience of major 
stressors in  prodromal & UHR,  5
– significant association:  ‘impaired 
tolerance of  normal stress’ and 
psychosis onset in UHR 6.
1.Bebbington et al, 1993, 2.Hirsch et al, 1996
3.Malla & Norman, 1992 , 4.Myin-Germeys et al (2001)  5. Miller et al, 2001), 6. Yung et al, 2005 
Social Functioning
• • Clinical High Risk subjects consistently
• demonstrate deficits equivalent to those
• seen in FE subjects in
• – current social functioning
• – premorbid social functioning
• – social cognition
• • facial affect recognition
• • social judgments
• Addington et al. 2008 Brit J Psych;
• Addington et al. 2008 Schiz Res
• Addington et al. 2008 Brit J Psych;
• Addington et al. 2008 Schiz Res
Social Functioning, social cognition 1,2
• Both UHR &  GHR show  
impairment, 
• UHR > GHR
• Duration of prodromal 
symptoms UHR– related -
impaired
• PS & NS - not significant
• Both a trait and state marker 
of risk schizophrenia / 
psychotic disorders,
• Mediating vulnerability
• Early indicator, 
• Prodromal stage- modest 
impairment
• Prefrontal dysfunction 
1.Shim G Social functioning deficits in young people at risk for 
schizophrenia.
, Aust N Z J Psychiatry. 2008 Aug;42(8):678-85
2.Chung YS, Deficit of theory of mind in individuals at ultra-
high-risk for schizophrenia
. Schizophr Res. 2008 Feb;99(1-3):111-8.
The theory of social defeat explains 
affective appraisal &  response for 
environmental factors enhancing 
risk for schizophrenia 
Marginalization, Social exclusion, Physical 
& Sex Abuse, Migration, Ethnicity increase 
prevailing risk level 
Social defeat, Environment & Enhanced 
Risk of SZ
• Previously, - proposed theory:  Long-
term experience of social defeat, 
defined as a subordinate position or 
as outsider status, may well be the 
common denominator for these 
findings 1
• This interpretation is compatible  
with the 
 High levels of competition in urban areas,
 Fewer career opportunities for people 
with low IQ, 
 Social exclusion experienced by 
immigrants and people with hearing 
impairments and 
 The humiliation of being abused
• Not Purely-Genetic risk 
factors: 
• urban environment, 
migration, 
• low IQ, 
• hearing impairment 2
• use of illicit drugs.
• Physical & sexual abuse 3
1.Selten & Cantor-Graae, 2005. 2.Thewissen et al, 2005  3.Read et al, 2005  
Search for Bio-markers
• Abnormal body movements, correlated with prodromal 
symptoms ( dopamine effect)
• Tendency to interpret nonsensical babbling as words and 
phases
• ‘ tendency to read meaning into meaningless sensory 
information may produce ‘ matrix of unreality’ that prompts 
initial psychotic phase.
Reduction in Mismatch negativity amplitude MMN &  
Heschl’s gyrus reduction
• Seen in chronic state
• Not seen in FES ( Umbricht et al 2006)
• Reduced by NMDA
• Involvement of auditory cortex in pathogenesis ( Salisbury et 
al 2007) schizophrenia
• Pathological changes are not confined to specific brain 
regions, PFC
Prodromal Syndrome
assessment tools 
• Identification by a structures interview
– Structured interview for prodromal syndrome (SIPS)
– Comprehensive Assessment of At Risk mental state ( 
CAARMS)
– Bonn scale for assessment of basic symptoms ( BSABS
• Syndromes
– Attenuated positive symptom syndrome
– Brief intermittent psychotic syndrome
– Genetic risk + deterioration syndrome
Variable Transition Rates
Study N Rate (%) Follow-up ( 
months
Current 
average 
33%
PACE (Aus) 104 35 12
PRIME (Yale) 13 54 12
PRIME (NA) 60 35 12
RAP (NY) 34 27 6
EDIE (UK) 23 22 12
CARE (SD) 50 15 12
Toronto 50 20 12
PAS, 
Newcastle, 
AUS
50 12
TOPP, Norway 43 12
Manchester 
(UK)
22 12
PACE (Aus), 
2006
9.2 6
• Declining TR @ 0.8 times at 
PACE(1995-2000)
• Explained by: 
• a- reduction in duration of 
symptom prior to help, 
• b-more false positive
Survival distribution function in North 
American study
6 12      18 24 30
Cannon et al. Arch Gen Psychiatry 2008;65:28-37
Transition Rate or 
Conversion to Psychosis depends upon the 
vulnerability of selected group
• Status Natural untreated transition in 
heterogeneous risk group
• Status of Preventable transition by a 
treatment (Non-drug or drug therapy)
• Selection is criteria dependent which 
leads to variability in transition rate.
NAPLS
“… prospective ascertainment of .. At risk for 
psychosis is feasible, with a level of predictive 
accuracy comparable to that in other areas of 
medicine”.. Tyrone Cannon
• N=291, F/U 30 months, 8 centers, tallied 77 individual 
predictors variables at base. 
• Variables covered 10 domains
• 5 additional criteria over SIPS increased chances of prediction 
by 80% 
• 35% TR, RR 405 in general population. 
UHR Status (CAARMS) 
• Sensitive (92%)predictor (TR  12/13 )
• Specificity was 62% Low functioning – as a 
predictor
Intervention
4-6 weeks 
pathogenesis
Early transition:
Severe progression
Late transition : 
ineffective treatment +  risk
Measurement of social and role functioning for 
assessment of UHR is challenging
• Cornblatt et al : two scales
• 1. Global Scale of functioning: Social
• 2.Global Scale of functioning: Role
• Excellent interrater reliability
• Functional decline as a risk 
• Functional improvement – a 
prognostic indicator in UHR
Good 
functioning
Inability to 
cope with 
Psychotic 
experience
Poor 
functioning
Psychosis
Community initiative & experience
‘highlight the need for comprehensive universal public mental 
health interventions’. 
• Educational campaign for destigmatization in a 
comparative study, Oslo, Norway: 
• Drop in suicidal behavior
• Age at first contact- reduced , younger with milder 
symptoms
• Shorter DUP
Linear
At-risk
FES
CSZ
Global Cognitive measure
Time Line 
*
*
*
*
*
*
** *
*
*
*
*
Cognition declines as psychosis progresses
Do Cognitive Deficits Progress During the 
Course of Schizophrenia? Yes, on all parameters
Cognitive Deficits
Cognitive performance profiles
intermediate to normal control and first
episode psychosis cohorts across domains
of attention, memory and executive ability.
Degree   of deficit at base does not predict psychosocial 
outcome.
The course of change in follow up does does differentiate good & 
poor functional outcome
Neurocognitive impairment in UHR
1.Working memory, 2.Executive Functioning  
• Represent neurocognitive trait as markers for SZ.
 Working memory, - consistently impaired throughout the course 1
 Working memory - impaired prior to the onset of psychotic illness 2
 Immediate verbal recall deficits - prior to illness onset, indicate 
compromised prefrontal functioning.
 Olfactory identification deficits - occur prior to psychosis onset 3. 
 despite this, --- predictive value of neurocognitive variables has 
proved to be disappointingly poor.
1. Goldman-Rakic, 1994, 2. Brewer et al, 2005, 3.(Brewer et al, 2001). 
Profile of Change in Mean Cognition 
 The origin of CI- unclear.
 some deficits are apparent prior to the onset
 if subjects with CI progress. unknown 
 there may be a specific decline in  visual memory and 
 attentional set-shifting, reflecting impairments in efficient 
organization of visual stimuli. 
 This may be caused by either the illness itself or treatment 
with antipsychotic medication. 
Whether cognitive function declined over the 
transition to psychosis? 
Wood SJ, Cognitive decline following psychosis onset: data from the PACE clinic
Br J Psychiatry Suppl. 2007 Dec;51:s52-7 .
Neurobiological- HPA
dysfunction may play a role
 Higher cortisol levels  
 Abnormal circadian cortisol 
rhythms Kaneko et al, 1992).
• N=12 UHR  participants
• Combined dexamethasone 
corticotrophin releasing hormone 
(DEX/CRH) test (Thompson et al, 
2007). 
• Over a 2-year, 3 of the 12 
participants developed  psychosis. 
• participants who did not make 
the transition
–  higher cortisol levels,
– Greater severity of 
depression- anxiety 
symptoms.  
• Dysregulated HPA-axis in UHR 
may represent ‘ comorbid 
depression’ rather than factors 
for process of emerging psychosis
Neuroplasticity provides foundation for 
possibility ‘re-generating’ neurons
Hypertrophy of brain Regions  using cognitive functions  
Intensive Computer based cognitive 
mediation as therapeutic 
intervention: NIHM Study
Navigation expertise and the human hippocampus: A structural brain imaging analysis
Eleanor A. Maguire: the experiment of London Taxi Drivers
Impaired Neuroplasticity in Schizophrenia and the 
Neuro-regenerative
• FES :  progressive loss of cortical and 
subcortical gray matter 1-6 
• childhood-onset SZ, cortical volume 
loss: 1%-3% per year during the first 5 
years.7
• High risk for SZ:  brain tissue loss during 
the transition.8
• Assumed –it was due to 
– brain atrophy, 
– neurotoxicity, or 
– neurodegeneration that involved 
– loss of neurons in the gray matter. 
• However, it has become apparent brain 
volume loss was due to:
– shrinkage of the neuropil 
surrounding the neurons, 9
– reduction in dendrite length by a 
half  
– decrease in number and size of 
dendritic extensions.10,11
• Furthermore,
– decline in neurotropin 3 (NT-3), 12
suggesting that 
– brain tissue loss during psychosis 
may be caused by a decline in 
growth factors that are critical in 
brain development, 
neuroplasticity, and 
– synaptic connectivity.
Imaging
• Findings generally demonstrate structural
• and functional changes post conversion
• but no differences to aid prediction
• Longitudinal increase in lateral ventricles, decrease in brain 
volume
• White matter & grey matter changes 
• Histropathological correlation?
Cavum septum pellucidum  (CSP)
in High risk subjects 
• Abnormal (CSP) [ is a space between the two leaflets of the septum 
pellucidum],
• no significant correlations with symptoms.1
• Reduced neurotransmitter function in CSP 2
• NT activity is reduced in UHR (N-acetylaspartateThe NAA concentrations of the 
UHR cases and FES -- correlated with the severity of negative symptoms). 2
1. Choi JS et al.  Cavum septum pellucidum in subjects at ultra-high risk for psychosis: compared with first-degree relatives of patients with 
schizophrenia and healthy volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;32(5):1326-30
2.Aydin K,   Altered metabolic integrity of corpus callosum among individuals at ultra high risk of schizophrenia and first-episode patients. Biol 
Psychiatry. 2008 Nov 1;64(9):750-7
1. Dysfunction maturational 
processes
2. loss of grey matter in DPFC 
3. Aberrant mechanisms for brain 
maturation, 
4. Subtle regionally and temporally 
specific  changes through the 
course of psychosis,  
(1) Early (pre- and perinatal) 
anomalies, 
(2) around the time of transition
(3) Late (post-pubertal) changes 
soon after the onset of psychosis, 
Consensus findings
• As yet there are no 
convincing, replicated, 
reports of neuroimaging 
measures that predict the 
subsequent onset of 
psychosis.
• Instead the most promising 
finding have been in Neuro-
psych. domain, with strong 
evidence for impairments in 
prefrontal cortex.
• The relative failure of 
neuroimaging measures to 
predict transition to psychosis 
suggests that standard volumetric 
techniques are incapable of 
capturing the subtle differences 
UHR with different outcomes
The brain developing in normal 
healthy youth
Time-lapse "movie" compresses 15 years of normal brain development (ages 5-20) into just a few seconds. Red indicates more gray matter, blue less 
gray matter. Gray matter wanes in a back-to-front wave as the brain matures and neural connections are pruned. Areas performing more basic functions 
mature earlier; areas for higher order functions mature later. The prefrontal cortex, which handles reasoning and other "executive" functions, emerged 
late in evolution and is among the last to mature.
Source: Gogtay N, Giedd JN, Lusk L, Hayashi KM, Greenstein D, Vaituzis AC, Nugent TF 3rd, Herman DH, Clasen LS, Toga AW, Rapoport 
JL, Thompson PM. Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A. 
2004 May 25;101(21):8174-9. Epub 2004 May 17. PMID: 15148381
COMT 
regulates DA 
turnover
NMDA Delays 
Brain 
Maturation
The brain developing in childhood onset schizophrenia
Time-Lapse MRI movie shows the brain developing in 12 teens with childhood onset schizophrenia. Areas of gray matter loss - red and yellow 
— spread from back-to-front over 5 years. These teens lost gray matter in the prefrontal cortex at 4 times the rate of normal health teens 
Source: Thompson PM, Vidal C, Giedd JN, Gochman P, Blumenthal J, Nicolson R, Toga AW, Rapoport JL. Mapping adolescent brain change 
reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11650-5. 
PMID: 11573002
Five Key Predictors
‘Poorer the social function & the more severe the unusual thought content & 
suspiciousness, closer was the person to onset of psychosis”
• Genetic risk with recent deterioration in function.
• Higher levels of unusual thoughts
• Higher level of suspicion or paranoia.
• Greater social impairment
• History of substance abuse
Intervention 
McGorry et al.,
2002, AGP
Melbourne
Morrison et al.,
2004, BJP
Manchester
McGlashan et al.,
2006, AJP
North America
6 month FU 12 month FU
12 month FU
N=59
12 months F/U
N=58
12 months F/U
N=60
10% -Risperidone & CBT
36% -needs based
9%-CBT
22-30% monitoring
16% - Olanzapine
35% - Placebo
42% stopped
risperidone
Dropout 13% for CBT, 14% 
for monitoring
Dropout – 55% for 
Olanzapine, 355 for 
Placebo
Three published studies : may be able to delay or 
even prevent onset of psychosis. 
Should Antipsychotics be used in Prodromal phase or at-risk SZ
1.Specific therapy V. need-based therapy (McGorry)
2. CONCLUSIONS: Without a specific treatment, 30-60% of 
persons    with UHR develop frank psychosis, 
3.Low-dose antipsychotic treatment seems to be effective 
4. in Prevention or
5. delay of psychosis.
Preventive Family intervention; Expressed Emotion (EE)
• Predictive of psychotic relapse (Bebbington & Kuipers,1994)
• ‘Not an artefact of patient morbidity’ (Leff and Vaughn,1995) 
• ‘Family intervention is recommended to reduce relapse risk’ 
(NICE, 2003)
McGorry PD, Yung AR Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis 
in a clinical sample with subthreshold symptoms, Arch Gen Psychiatry. 2002 Oct;59(10):921-8 
Cognitive therapy
Vs. monitoring : 
• only conducted by the Early 
Detection and Intervention (EDIE) 
group  Manchester showed a 
significant effect of the 
treatment.
Treatment 
Group
Follow-up Rate
N (%)
PANNS 
Transition
N (%)
Antipsychotic 
Medication
N (%)
DSM-IV 
Psychotic 
Diagnosis
N (%)
Cognitive 
Therapy (N = 35)
17 (49%) 7 (20%) 5 (14%) 7 (20%)
Monitoring 
(N = 23)
10 (43%) 5 (22%) 8 (35%) 7 (30%)
Morrison et al, 2004
Second-Generation Antipsychotics
• In contrast to haloperidol, several SGAs were reported to 
stimulate
• Neurogenesis in the adult rat, except for clozapine, which 
according to 2 reports has no effect. 
• Studies with olanzapine have shown:
• Increased neurogenesis in the hippocampus
• Increased hippocampal neurogenesis after 28 days
• No change in the hippocampus but an increased proliferation in 
the prefrontal cortex,
• This result indicate: A delay in the onset of psychosis 
•
Yung AR, Yuen HP, Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71.
‘Olanzapine versus 
supportive therapy and 
monitoring 
• showed a trend 
• in effectively preventing
• or delaying psychosis 
(McGlashan et al, 2006).
• Tx Gr.- lower levels of 
‘Prodromal’ Symptomatology
• the clinical benefit, terms of 
transition rates, was more 
equivocal. 
• In all, results of these first  
treatment trials suggest that both 
antipsychotic
medication and psychological 
interventions might have a role in 
treating the difficulties and 
problems young people at ultra-
high risk experience as well as 
delaying or preventing the onset 
of psychosis.
Conclusion 
• Identification & prediction  involve using different 
combinations of genetic, age range and symptomatic risk 
factors. 
• However, even using these multiple-gate screening models, 
the majority of those selected still do not develop the 
disorder. 
• This aids our detection of  individuals in whom indicated 
preventive intervention may be justified. 
• Arriving at a PPV of 100% would be a clear indication for 
pharmacological treatment in the identified group. 
